Enodia Therapeutics acquires Kezar's Sec61 preclinical assets for $127M

March 12, 2026 9:00 AM

Enodia Therapeutics has acquired preclinical assets from Kezar Life Sciences' (NASDAQ: KZR) Sec61-based discovery and development program under a deal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found